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Objectives. The purpose of this analysis was to define the
factors that predict 3-year graft patency.
Background. The success of coronary artery bypass graft sur-
gery (CABG) is dependent on vein graft patency after the opera-
tion. It has been well established by a series of Department of
Veterans Affairs Cooperative Trials that aspirin (325 mg daily)
improves saphenous vein graft patency early (7 to 10 days) and at
1 year, but not at 3 years after CABG. This analysis, based on one
of these trials, defined factors that predict 3-year graft patency.
Methods. This analysis consisted of 266 patients, with 656
grafts that were patent 7 to 10 days after the operation, who
underwent 3-year catheterization. To determine which patient-
specific and/or graft-specific factors, or both, predict graft occlu-
sion, a multivariate logistic regression analysis in terms of latent
variables was used. It yielded a model that also took into account
possible intraclass correlations.
Results. For a vein graft that was patent at 7 to 10 days after the
operation, the positive predictors, according to univariate analy-
sis, for that graft being patent at 3 years were cross-clamp time
<280 min (p < 0.001), vein preservation solution temperature
<25°C (p 5 0.009), bypass time <22 h (p 5 0.042), number of
proximal anastomoses <22 (p 5 0.018), operation time <25 h (p 5
0.044) and continuous versus intermittent cross-clamp technique
(p 5 0.024). There was also a trend with regard to recipient artery
diameter >1.5 mm (p 5 0.063), serum cholesterol <2225 mg/dl
(p 5 0.084) and single versus sequential or Y vein graft (p 5
0.060). Factors not predictive of 3-year patency were age, race,
smoking history, high density lipoprotein cholesterol, vein source
(thigh vs. calf), coronary artery grafted and aspirin treatment. Of
all the predictors obtained in the univariate analysis, the only
variables that were sufficient to yield a good model within the
multivariate analysis were solution temperature (p 5 0.004),
serum cholesterol (p 5 0.024), number of proximal anastomoses
(p 5 0.032) and recipient artery diameter (p 5 0.034).
Conclusions. For a patient with patent vein grafts 7 to 10 days
after the operation, predictors of 3-year graft patency are more
closely related to operative techniques and underlying disease and
not to aspirin treatment.
(J Am Coll Cardiol 1997;29:1563–8)
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The long-term success of coronary artery bypass graft surgery
(CABG) is dependent on graft patency after the operation. It
is now well established that aspirin (325 mg daily) improves
saphenous vein graft patency early (7 to 10 days) and at 1 year,
but not at 3 years after CABG (1–5). This information was
established by a series of Department of Veterans Affairs
Cooperative Trials designed to determine the effects of aspirin
on saphenous vein graft or internal mammary artery (IMA)
graft patency after CABG.
The results presented in this report are based on an analysis
of the factors that predict 3-year vein graft patency, given that
the operation has been a success (i.e., there is at least one
patent saphenous vein graft 7 to 10 days after CABG). The
status of a graft known to be patent at 7 to 10 days was assessed
at 1 year and 3 years after the operation. This approach to analysis
of vein graft patency eliminates any graft occlusion that occurred
as a perioperative event and permits us to examine only those
factors that cause vein graft occlusion after the graft has been
shown to be patent. A multivariate logistic regression analysis in
terms of latent normal variables (6) was used to model the data.
The model yielded the most important patient-specific and graft-
specific factors predicting graft occlusion.
Methods
Study group. This trial, organized by the Cooperative
Studies Program of the Department of Veterans Affairs Med-
ical Research Service, consisted of data from 266 male patients
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entered into the study at 10 participating hospitals from July
1986 to September 1988. Patient follow-up was concluded in
1991. The exclusion criteria, definition of the study group and
stratification techniques have been previously described (1–5).
Of the total 374 patients who underwent catheterization 1
year postoperatively, 334 (89%) agreed to participate in the
long-term phase of the study and were randomized and
prospectively followed for an additional 2 years. Although
there were 297 patients, with 779 grafts, who underwent
catheterization 3 years postoperatively, the data set for this
report consists of the 266 patients, with 656 grafts, who were
known to have patent grafts 7 to 10 days after the operation.
Treatment regimens. After receiving aspirin (325 mg daily)
for 1 year after the operation and undergoing catheterization 1
year postoperatively, patients were randomized to receive
either aspirin (325 mg) or placebo for the next 2 years. The
aspirin and matching placebo were provided by Glenbrook
Laboratories. All medications were provided in individualized
patient kits. Compliance testing was assessed with pill counts,
as noted previously (2). To ensure that patients took only their
study medications, Disalcid (salsalate) was made available to
all patients, and patients were instructed to take either the
salsalate or acetaminophen for pain. In addition, to minimize
the risks of patients unknowingly taking aspirin-containing
compounds, a list of all over-the-counter medications contain-
ing aspirin was given to each patient.
Coronary artery bypass grafting. Bypass grafting was
achieved by the usual protocol at each of the study institutions.
The decision to use the IMA or saphenous vein as a conduit
was made by the attending surgeon. If the determination was
made preoperatively by the surgeon to use both IMA and
saphenous vein grafts, the patient was eligible for the study. If
the determination was made preoperatively by the surgeon to
use only IMA grafts, the patient was not randomized, because
the primary objective of the study was to assess the effect of
aspirin on the 3-year patency of saphenous vein grafts. The
saphenous vein and IMA grafts were included in separate
analyses.
Although no attempt was made to establish a uniform
technique for performing the operation, those institutions
chosen to participate in the study were selected on the basis of
experience and competence as documented by yearly statistics
compiled by the Department of Veterans Affairs Central
Office. Detailed data forms covering technical aspects of the
perfusion, cardioplegic solutions, time of operation, arrest
period, technical considerations regarding vessel and graft size,
postoperative support and bleeding were maintained for each
patient.
Angiographic analysis. The angiographic analysis used in
this study was identical to that in our earlier trials (1–5).
Briefly, the left IMA and each aortic anastomosis was selec-
tively engaged and injected. When the status of a vein graft
could not be determined by graft or stump injection, an aortic
root angiogram was performed. Selective angiography of the
native coronary arteries was performed during the 1-week and
1-year catheterizations only when a graft was occluded. Selec-
tive angiography of the native coronary arteries was routinely
performed at the 3-year catheterization. All angiograms were
interpreted at both the participating institutions and the
central angiographic laboratory. The data from the central
angiographic laboratory were used for this report. At the
central angiographic laboratory, each angiogram was inter-
preted independently by two cardiovascular radiologists who
had no knowledge of the patients’ treatment regimen. The
analysis was performed with a system developed for this study,
which included a Vanguard projector and high resolution
television camera (Vanguard Instrument Corp.) to record the
images. The images were digitized and the information entered
into an integrated image processor-computer system. The
images were then redisplayed on the integrated memory plane,
absolute measurements made and stenoses calculated for all
vessels $1 mm in diameter. The number, type and size of all
grafts were recorded using an interactive computer program.
Images of the cine frames, with the measurements superim-
posed, were filmed for storage in hard copy format. The
angiographic analysis used in this study was prospective. The
size of the distal vessel was analyzed by measuring the lumen of
the vessel from the cine film. To determine the absolute lumen
diameter of the distal vessel, the diameter of the catheter was
measured. The appropriate magnification factor was calculated
by knowing the actual diameter of the catheter. Actual vessel
size was reported using this correction factor.
A single vein or IMA graft was defined as patent when the
origin was visualized and the contrast agent opacified the graft
and the distal vessel, either by selective injection or by aortic
root angiography. When analyzing sequential or Y vein grafts,
a distal anastomosis (either side to side or end to side) was
defined as patent if the contrast medium was seen to flow from
the vein graft into the grafted artery. If the graft was occluded
at its origin, all associated distal anastomoses were considered
occluded. If one distal anastomosis of a Y or sequential vein
graft was occluded, that site was defined as an occluded graft.
When there was a difference of opinion regarding patency, the
films were reviewed and a consensus opinion was reported.
Statistical analysis. The technique used for data collection
did not supply continuous information on the occlusion pro-
cess in time, but only some binary values, occluded or patent,
at discrete moments in time. Therefore, analyses based on the
logistic regression model (for clustered binary data) with latent
normal variables (6) were applied. In such models, the occlu-
sion process is described by a function that determines the
outcome of an observable binary variable (occluded or not)—
that is, one can assume that the outcome (occlusion of graft)
was the realization of an unobservable (latent) continuous
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variable and that occlusion occurred only if the latent variable
exceeded a certain level. For the ith patient (i 5 1, . . ., 266),
the probability pijt that the jth graft (j 5 1, . . ., ni) at the time
t of the 1-year or 3-year angiogram is occluded is equal to the
probability that the corresponding (to the given graft) latent
variable is greater than zero. The marginal probability pijt is
determined by covariates xij 5 (xijl, . . ., xijp)9 (p is the number
of covariates) in the frame of the generalized linear model logit
(pijt) 5 xij9b. Vector b has the form b 5 (b1, . . ., bp),9 where
br is the log odds ratio when xijr is increased by 1. The
tetrachoric correlation, which measures the dependence be-
tween outcomes (e.g., between yikt and yijt [k Þ j]) is the
correlation between realizations of a pair of relevant latent
continuous variables. These variables are assumed to be biva-
riate standard normally distributed.
First, a univariate analysis was performed to obtain primary
information on important predicting factors. Then multivariate
analysis was carried out using important factors found in the
previous analysis. The model was built in such a way that
different variables were forced to be in the model. Model
stability (i.e., the influence of each subject on the estimates of
covariates) was chosen as the criterion for the final model. For
the selection of the model and checking of the model fit to the
empiric data, the jackknife method was used.
Results
Patient data. The details of the patient data, including
clinical outcomes and complications of the catheterizations,
have been reported previously (1–5). Of the original 334
patients who were randomized at 1 year postoperatively, 297
patients underwent 3-year angiography. Of the 37 patients
excluded, there were seven deaths and no myocardial infarc-
tions or revascularization procedures. The remaining 30 pa-
tients who were excluded either withdrew from the study or
refused the 3-year catheterization. Of the 297 patients who
underwent 3-year angiography, 31 were excluded from this
report because they did not undergo the 7- to 10-day postop-
erative catheterization, so it was not known whether their
grafts were patent after the operation.
In brief, the data are from 266 (80%) of the original 334
patients with patent saphenous vein grafts at 7 to 10 days who
had cardiac catheterization at 1 and 3 years after the operation
and whose data were available in the central angiographic
laboratory. The median time from CABG to 1-year catheter-
ization was 1 year (range 0.2 to 1.5). Ninety percent of the
1-year catheterizations were done between 0.9 and 1.1 years
after the operation. The median time from CABG to 3-year
catheterization was 3 years (range 1.7 to 4.8). Ninety percent of
these catheterizations were done between 2.8 years and 3.2
years after the operation.
The baseline clinical characteristics have been reported
previously (1,4,5). The only difference observed in clinical
characteristics was related to smoking history. Among patients
who underwent the 3-year postoperative catheterization,
18.8% never smoked, compared with 6.5% for patients who
were not catheterized (p 5 0.041). There were no incidences of
myocardial infarction, stroke or death during the 3-year post-
operative catheterizations.
Vein graft data. In these 266 patients, there were 656
saphenous vein grafts—473 single, 148 sequential and 35 Y
grafts.
The results of univariate analysis for vein graft occlusion are
presented in Tables 1 to 3. For a saphenous vein graft that was
patent 7 to 10 days after CABG, the following were positive
predictive factors for that graft being patent 3 years after the
Table 1. Potential Preoperative Patient-Specific Predictors of 3-Year









Aspirin 128 (321) 12.5 0.323
No aspirin 130 (313) 15.3
Age (yr)
#50 29 (60) 11.7 0.360
.50 237 (596) 14.8
Race
Nonwhite 25 (67) 10.4 0.514
White 241 (587) 14.9
Smoking
No 163 (390) 14.1 0.492
Yes 102 (264) 15.2
Serum cholesterol (mg/dl)
#225 144 (349) 10.0 0.084
.225 99 (244) 17.2
Serum HDL (mg/dl)
#30 71 (169) 13.0 0.390
.30 88 (235) 9.8
HDL 5 high density lipoprotein; Pts 5 patients.
Table 2. Potential Intraoperative and Perioperative Patient-Specific








No. of proximal anastomoses
#2 66 (132) 10.6 0.018
.2 200 (524) 15.5
Operation time (h)
#5 199 (492) 12.8 0.044
.5 65 (157) 20.4
Bypass time (h)
#2 167 (376) 12.0 0.042
.2 98 (278) 18.0
Cross-clamp time (min)
#80 225 (535) 11.2 , 0.001
.80 40 (119) 29.4
Vein preservation solution temp (°C)
#5 104 (264) 8.3 0.009
.5 161 (389) 18.8
Cross-clamp technique
Continuous 228 (571) 13.5 0.024
Intermittent 37 (83) 21.7
Pts 5 patients; temp 5 temperature.
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operation: cross-clamp time #80 min (p , 0.001), vein pres-
ervation solution temperature #5°C (p 5 0.009), bypass time
#2 h (p 5 0.042), number of proximal anastomoses #2 (p 5
0.018), operation time #5 h (p 5 0.044) and continuous versus
intermittent cross-clamp technique (p 5 0.024). These factors
showed a trend: recipient artery diameter .1.5 mm (p 5
0.063), serum cholesterol #225 mg/dl (p 5 0.084) and single
versus sequential vein graft (p 5 0.060). The following were
not predictive of 3-year graft patency: age, race, smoking
history, high density lipoprotein cholesterol, vein source (thigh
vs. calf), coronary artery grafted and aspirin treatment.
The results of multivariate analysis are presented in Table
4. In the final model we included the following variables that
were independent predictors of 3-year graft patency: vein
preservation solution temperature (p 5 0.004), serum choles-
terol (p 5 0.024), diameter of recipient artery (p 5 0.034) and
number of proximal anastomoses (p 5 0.032). Table 4 also
contains the tetrachoric correlations alpha1 and alpha2. Only
the correlation alpha2 is significant. Thus, the occurrence of
occlusion or patency of two grafts for the same patient is
significantly correlated only for an angiogram performed either
at the 1-year or 3-year period.
The following are the data on whether graft narrowing was
a predictor of graft occlusion: At 7 to 10 days, 40 grafts were
totally occluded and five grafts had stenoses. At 1 year, 102
grafts were totally occluded and 12 grafts had stenoses. With so
few cases of graft narrowing, the degree of stenosis is nearly
identical to our binary outcome variable.
IMA grafts. There were 167 IMA grafts that were patent at
7 to 10 days. Twelve of these grafts became occluded within 3
years (93% patency). The logistic univariate analysis indicated
low body temperature as an important occlusion predictor
(p 5 0.0057). In a second type of univariate analysis (7),
significant differences for the occlusion ratio estimates were
observed for the following variables: previous myocardial
infarction (yes, no), smoking (yes, no) and categorized low
body temperature (#28°C, .28°C). However, there were so
few occurrences of occlusions, that the aforementioned results
should be treated only as trend indicators.
Discussion
This analysis shows that for a patient who undergoes
successful CABG with a patent saphenous vein graft 7 to 10
days after operation, in addition to serum cholesterol being a
predictor of 3-year vein graft patency, the other patient-
specific predictors are related to operative techniques, such as
bypass and cross-clamp times, and vein preservation solution
temperature. Recipient artery diameter and use of single
versus sequential vein grafts were graft-specific predictors of
3-year patency. Importantly, treatment with aspirin was not
predictive of 3-year vein graft patency. Because this report
includes only vein grafts that were known to be patent at 7 to
10 days, the factors we identified are the most accurate
predictors of long-term vein graft patency. Previous investiga-
tors have examined clinical characteristics or operative data
and used this information to define predictors of long-term
vein graft patency (2,5). This latter approach does not take into
account the fact that 7% to 10% of vein grafts occlude within
the first week of CABG and another 5% to 10% occlude in the
first year after the operation (1,2). The approach outlined here
examines prospectively only saphenous vein grafts that were
known to be patent at 7 to 10 days. Therefore, the risk factors
identified here predict what happens to a vein graft after the
patient has undergone “successful CABG.”
Causes of graft occlusion. The anatomic descriptions of
the causes of saphenous vein graft occlusions are based on
clinicopathologic studies that suggest vein graft occlusion in
the perioperative period is due to thrombosis resulting from
technical problems. Vein graft occlusion within the first year is
attributed to intimal proliferation, although after 1 year,
atherosclerosis is thought to be the dominant factor (8,9).
Table 3. Potential Graft-Specific Predictors of 3-Year Graft





Grafts (%) p Value
Diameter (mm)
#1.5 77 (110) 22.7 0.063
.1.5 259 (546) 12.8
Source of vein
Thigh 117 (204) 12.7 0.449
Calf 206 (441) 15.6
Type of graft
Single vein grafts 241 (473) 12.3 0.060
Sequential/Y vein grafts 80 (183) 20.8
Artery grafted
RCA/LCx 254 (458) 14.0 0.885
LAD 152 (198) 15.7
LAD 5 left anterior descending coronary artery (includes grafts to the
diagonal and ramus intermedius); LCx 5 circumflex coronary artery; RCA 5
right coronary artery.
Table 4. Multivariate Analysis: Coefficient and Standard Errors for
Logistic Regression Equation for Model in Which Patient, Graft





Intercept 24.1328 0.7777 , 0.001
Solution temp
(#5°C 5 0, .5°C 5 1)
0.9783 0.3314 0.004
Serum cholesterol 0.0060 0.0028 0.024
No. of prox anastomoses
(#2 5 0, .2 5 1)
0.9724 0.4282 0.032
Recipient artery diameter 20.3766 0.1770 0.034
Alpha1 0.1873 0.1083 0.090
Alpha2 0.2811 0.1061 0.009
Alpha1 5 tetrachoric correlation between observations on different grafts for
the same patient during different angiographic examinations; Alpha2 5 tetra-
choric correlation between observations on different grafts for the same patient
during the same angiographic examination; prox 5 proximal; other abbreviations
as in Table 2.
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Although this description is generally well accepted, it does not
account for the specific pathophysiologic processes that result
in long-term vein graft occlusion. Previous trials from our
group (1–5) and others (10–13) have focused on the use of
specific antiplatelet agents to improve vein graft patency. The
fact that aspirin in the perioperative period, which is continued
for 1 year, is effective in reducing vein graft occlusion rates
supports the concept that platelet deposition and thrombosis
play an important role in vein graft occlusion within 1 year of
CABG. Likewise, our previous data showing that aspirin
treatment between years 2 and 3 does not result in any
improvement in vein graft patency support the pathologic
interpretation that the development of atherosclerosis in the
vein graft and not thrombosis is the most important factor in
determining long-term vein graft patency.
Operative factors. It is interesting that our data demon-
strate that operative factors, such as bypass and cross-clamp
times, affect long-term graft patency. Our assumption is that
the correlation of longer operating times resulting in higher
graft occlusion rates at 3 years is due to the fact that the
patients with longer operating times were those who required
additional revascularization. This is supported by the fact that
patients with longer operative times had a larger average
number of grafts (cross-clamp time .80 min for 1.98 [average]
grafts; cross-clamp time #80 min for 1.86 grafts; bypass time
.2 h for 2.05 grafts; bypass time #2 h for 1.88 grafts).
Vessel diameter. The diameter of the recipient vessel was a
determinant in long-term vein graft patency because veins
grafted into smaller vessels have higher occlusion rates. We
and others have shown this to be true at 1 week, 1 year and 3
years after CABG (1,2,5). In fact, our earlier reports suggest
that aspirin is most effective in vein grafts placed to smaller
vessels because vein grafts to vessels $2.0 mm remain patent
even if the patient is not treated with aspirin.
Graft type. The data on single versus sequential or Y vein
grafts show a trend for improved 3-year graft patency for those
patients who had one aortic anastomotic site for each vein
graft. These data are in conflict with the approach taken by
surgeons in the 1980s, who promoted the use of a single aortic
anastomosis with multiple distal runoff sites to improve flow
through the graft so it would remain patent longer. Because
the surgeons in the present study did not randomize the
patients in terms of single versus sequential or Y grafts, our
data should not be regarded as proof that vein grafts with
multiple distal sites do poorly. It is possible that the patients
with sequential grafts in this study may have had more
atherosclerotic disease in their aortas and more distal coronary
artery disease as well.
Serum cholesterol. Data now show that treating patients
with an elevated serum cholesterol with the 3-hydroxy-3-
methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors
or “statins” is an effective means of secondary prevention of
cardiovascular morbidity and mortality in patients with preex-
isting coronary artery disease (14). Although studies like these
will probably change clinical practice, they do not specifically
address patients after CABG and do not examine the effects of
serum cholesterol on vein graft patency. It is interesting to note
the conflicting data generated within our own study group in
defining the effects of serum cholesterol as a predictor of vein
graft occlusion. For example, in our previous analysis, when we
attempted to use baseline characteristics to predict 3-year vein
graft patency, the baseline serum cholesterol was not useful
(5). However, in this vein graft survival analysis, in which the
patient had to have one patent vein graft at 7 to 10 days, a
serum cholesterol level .225 mg/dl predicted 3-year vein graft
occlusion. Because the current report examines only those
patients with a patent vein graft, these data are probably a
more accurate reflection of the pathophysiology of vein graft
occlusion. Other data to support that serum cholesterol may be
a predictor of vein graft occlusion are the Cholesterol Lower-
ing Atherosclerosis Study (CLAS) results (15). These investi-
gators showed that colestipol and niacin in combination re-
sulted in a 43% reduction in high density lipoprotein
cholesterol, and although this regimen did not alter vein graft
patency, this treatment did decrease the development of new
lesions in vein grafts. In addition, a 10-year study from the
Montreal Heart Institute showed that serum cholesterol levels
were significantly higher at the time of CABG and at the
10-year postoperative catheterization in those patients who
developed new lesions in their vein grafts (9,16,17).
Solution temperature. The predictive effects of using a
lower temperature for preparation of the vein graft is interest-
ing. To our knowledge, this is the first report suggesting that
the temperature of the vein perfusate solution has an effect on
long-term patency. Most other investigators who studied vein
graft preparation techniques examined short-term patency and
looked at factors that result in mechanical damage (i.e., using
low vs. high pressure distention or different vasodilating solu-
tions) (18). The general conclusions from these studies were
that endothelial damage and vasospasm during the preparation
of the saphenous vein for bypass grafting may be an important
cause of graft failure. One report suggested that these factors
may be responsible for 12% to 20% of venous grafts that
occlude during the first year (19). Because of this, current
surgical practice emphasizes improvement in surgical handling
techniques, lower inflation pressure during the leak testing and
different preservation media to improve graft patency. More
recent data showed improvement in endothelial preservation
in vein grafts when perfused with cold (4°C) saline or the
University of Wisconsin solution compared with heparinized
blood (20). Interestingly, the importance of the temperature of
the perfusion fluid is also thought to be important during
donor heart preservation before heart transplantation, because
vessel endothelium tends to degenerate if preserved in normal
saline at room temperature, although it can be well preserved
in cold saline (4°C) for 4 to 6 h (21).
IMA grafts. The number of IMA graft occlusions (12 in
167 patients) were too few to analyze. Nevertheless, these data
are interesting and demonstrate that although IMA graft
occlusion may be rare, our 3-year IMA occlusion rate of 7.2%
shows that some of these grafts do occlude. Although previous
reports suggest 10-year patency rates of 90% to 95% for IMA
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grafts (22), it is important to note that this information was not
obtained from prospectively designed trials. In addition, the
patients who were operated on in the 1970s, before the use of
IMA grafts became widespread, were probably better candi-
dates than those who receive IMA grafts today (i.e., larger
distal left anterior descending coronary arteries and better
runoff). Most importantly, when patients operated on in the
1980s are studied prospectively, the 10-year patency rate will
probably be lower than 90%.
Statistical model. In our statistical analysis we concen-
trated on the problems of finding the most important predic-
tors of long-term saphenous vein graft patency and possible
correlations at the patient, graft and time levels. The baseline
information on patient-specific and graft-specific covariates
was utilized. We based the analysis on the concept of latent
variables for clustered data (6). Such an approach was used
because catheterization supplies information on graft patency
only at discrete moments of time, whereas graft occlusion is a
continuous process, and we could simultaneously take into
account both types of covariates and multilevel correlations.
By means of univariate analysis, we carried out the first
selection of predictors and then we tried to build an adequate
multivariate logistic regression. The data were modeled in such
a way that the marginal outcome probabilities were deter-
mined by means of covariates in the frame of a logistic linear
model. Therefore, the coefficients in the regression equation
could be interpreted as population-average logarithms of
adjusted odds ratios.
For selection of a final model and checking of its stability,
we applied the jackknife diagnostic tool. In this method, we
looked for the change of beta estimates by recomputing the
model for a data set with the ith patient deleted. Among the
results, the jackknife method indicated that the recipient artery
diameter applied as a continuous variable yielded more stable
models than the use of categorized diameter. The final model
chosen included solution temperature, number of proximal
anastomoses, serum cholesterol and recipient artery diameter.
It is worth noting, however, that the cross-clamp time was not
included in the model because of its high correlation with the
number of proximal anastomoses. Finally, we tried to obtain
information on possible intraclass correlations and their ori-
gins. From Table 4, we can conclude the existence of some
correlations among the observations from an individual patient
for different times after CABG and different grafts, but the
main correlation is the one among observations taken for a
given patient but different grafts either at the 1-year or 3-year
postoperative angiogram. A detailed description of the statis-
tical analysis performed by us will shortly be published (23).
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